Top

Published in:

01-08-2014 | Original paper

The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort

Authors: Alexis R. Gaines, Elizabeth L. Turner, Patricia G. Moorman, Stephen J. Freedland, Christopher J. Keto, Megan E. McPhail, Delores J. Grant, Adriana C. Vidal, Cathrine Hoyo

Published in: Cancer Causes & Control | Issue 8/2014

Abstract

Purpose

Population-based studies have established a link between race and prostate cancer (PC) risk, but whether race predicts PC after adjusting for clinical characteristics is unclear. We investigated the association between race and risk of low- and high-grade PC in men undergoing initial prostate biopsy in an equal access medical center.

Methods

We conducted a retrospective record review of 887 men (48.6 % black, 51.4 % white) from the Durham Veterans Affairs Medical Center who underwent initial prostate biopsy between 2001 and 2009. Multivariable logistic regression analysis of race and biopsy outcome was conducted adjusting for age, body mass index, number of cores taken, prostate-specific antigen (PSA), and digital rectal examination findings. Multinomial logistic regression was used to test the association between black race and PC grade (Gleason <7 vs. ≥7).

Results

Black men were younger at biopsy (61 vs. 65 years, p < 0.001) and had a higher pre-biopsy PSA (6.6 vs. 5.8 ng/ml, p = 0.001). A total of 499 men had PC on biopsy (245 low grade; 254 high grade). In multivariable analyses, black race was significantly predictive of PC overall [odds ratio 1.50, p = 0.006] and high-grade PC [relative risk ratio (RRR) 1.84, p = 0.001], but was not significantly associated with low-grade PC (RRR 1.29, p = 0.139).

Conclusion

In an equal access healthcare facility, black race was associated with greater risk of PC detection on initial biopsy and of high-grade PC after adjusting for clinical characteristics. Additional investigation of mechanisms linking black race and PC risk and PC aggressiveness is needed.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166 PubMedCrossRef

Brawley OW, Knopf K, Thompson I (1998) The epidemiology of prostate cancer part II: the risk factors. Semin Urol Oncol 16(4):193–201PubMed

Freedland SJ, Isaacs WB (2005) Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 62(3):243–252. doi:10.1002/pros.20052 PubMedCrossRef

Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, Yu K, Chatterjee N, Welch R, Hutchinson A, Crenshaw A, Cancel-Tassin G, Staats BJ, Wang Z, Gonzalez-Bosquet J, Fang J, Deng X, Berndt SI, Calle EE, Feigelson HS, Thun MJ, Rodriguez C, Albanes D, Virtamo J, Weinstein S, Schumacher FR, Giovannucci E, Willett WC, Cussenot O, Valeri A, Andriole GL, Crawford ED, Tucker M, Gerhard DS, Fraumeni JF Jr, Hoover R, Hayes RB, Hunter DJ, Chanock SJ (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40(3):310–315. doi:10.1038/ng.91 PubMedCrossRef

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294(4):433–439PubMedCrossRef

Johnstone PA, Kane CJ, Sun L, Wu H, Moul JW, McLeod DG, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat MG, Foley J, Baldwin D, Soderdahl D, Do J, Amling CL (2002) Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the department of defense center for prostate disease research. Radiology 225(2):420–426PubMedCrossRef

Fowler JE Jr, Terrell F (1996) Survival in blacks and whites after treatment for localized prostate cancer. J Urol 156(1):133–136PubMedCrossRef

Roach M III, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D (2003) Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol 169(1):245–250PubMedCrossRef

Powell IJ, Schwartz K, Hussain M (1995) Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology 46(6):825–830. doi:10.1016/S0090-4295(99)80352-5 PubMedCrossRef

10.

Hamilton RJ, Aronson WJ, Presti JC Jr, Terris MK, Kane CJ, Amling CL, Freedland SJ (2007) Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer 110(10):2202–2209

11.

Yanke BV, Carver BS, Bianco FJ Jr, Simoneaux WJ, Venable DD, Powell IJ, Eastham JA (2006) African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram. BJU Int 98(4):783–787. doi:10.1111/j.1464-410X.2006.06388.x PubMedCrossRef

12.

Kubricht WS, Kattan MW, Sartor O, Eastham JA (1999) Race is not independently associated with a positive prostate biopsy in men suspected of having prostate cancer. Urology 53(3):553–556PubMedCrossRef

13.

Tsivian M, Banez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik TJ (2012) African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis. doi:10.1038/pcan.2012.39

14.

Polednak AP (2002) Black-white differences in tumor grade (aggressiveness) at diagnosis of prostate cancer, 1992–1998. Ethn Dis 12(4):536–540PubMed

15.

US Department of Veterans Affairs (2013) About the Durham Veterans Affairs Medical Center. US Department of Veterans Affairs, Washington, DC

16.

US Department of Veterans Affairs (2012) Health benefits: veteran eligibility. US Department of Veterans Affairs, Washington, DC

17.

US Census Bureau (2011) American Community Survey, public use microdata sample (PUMS). US Department of Commerce, Washington, DC

18.

Department of Defense (2011) Population representation in the military services fiscal year 2011 report. Washington, DC

19.

Zullig LL, Jackson GL, Dorn RA, Provenzale DT, McNeil R, Thomas CM, Kelley MJ (2012) Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. Mil Med 177(6):693–701PubMedCentralPubMedCrossRef

20.

Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM (2000) Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med 160(21):3252–3257PubMedCrossRef

21.

Moreira DM, Anderson T, Gerber L, Thomas JA, Banez LL, McKeever MG, Hoyo C, Grant D, Jayachandran J, Freedland SJ (2011) The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series. Cancer Causes Control 22(7):977–983. doi:10.1007/s10552-011-9770-3 PubMedCrossRef

22.

Pierorazio PM, Walsh PC, Partin AW, Epstein JI (2013) Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 111(5):753–760. doi:10.1111/j.1464-410X.2012.11611.x PubMedCentralPubMedCrossRef

23.

Howlader NNA, Krapcho M et al (2013) SEER cancer statistics review, 1975–2010. National Cancer Institute, Bethesda

24.

Odedina FT, Akinremi TO, Chinegwundoh F, Roberts R, Yu D, Reams RR, Freedman ML, Rivers B, Green BL, Kumar N (2009) Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa. Infect Agents cancer 4(Suppl. 1):S2. doi:10.1186/1750-9378-4-S1-S2 PubMedCentralPubMedCrossRef

25.

Powell IJ (2007) Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 177(2):444–449. doi:10.1016/j.juro.2006.09.024 PubMedCrossRef

26.

Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 98(8):529–534. doi:10.1093/jnci/djj131 PubMedCrossRef

27.

Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E (2010) Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol 28(10):1714–1720. doi:10.1200/JCO.2008.20.3422 PubMedCentralPubMedCrossRef

28.

Carver BS, Bozeman CB, Simoneaux WJ, Venable DD, Kattan MW, Eastham JA (2004) Race is not a predictor of prostate cancer detection on repeat prostate biopsy. J Urol 172(5 Pt 1):1853–1855PubMedCrossRef

29.

Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O (1998) Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 16(9):3101–3104PubMed

30.

US Preventive Services Task Force (2012) Screening for prostate cancer: final recommendation statement. AHRQ Publication No. 12-05160-EF-2. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs.htm. (Accessed June 2013)

31.

Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL (2013) Early detection of prostate cancer: AUA guideline. J Urol 190(2):419–426. doi: 10.1016/j.juro.2013.04.119

32.

Carpenter WR, Beskow LM, Blocker DE, Forlenza MJ, Kim AE, Pevzner ES, Rose JM, Tran AN, Webber KH, Knight K, O’Malley MS (2008) Towards a more comprehensive understanding of cancer burden in North Carolina: priorities for intervention. N C Med J 69(4):275–282PubMedCentralPubMed

33.

Porterfield D, Knight K (2006) Running the numbers: a periodic feature to inform North Carolina healthcare professionals about current topics in health statistics. N C Med J 67(3):235–236

34.

Nixon RG, Meyer GE, Brawer MK (1999) Differences in prostate size between patients from university and Veterans Affairs Medical Center populations. Prostate 38(2):144–150PubMedCrossRef

35.

Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl.):IV-3–IV-18. doi:10.1097/01.MLR.0000020942.47004.03

36.

Boyko EJ, Koepsell TD, Gaziano JM, Horner RD, Feussner JR (2000) US Department of Veterans Affairs medical care system as a resource to epidemiologists. Am J Epidemiol 151(3):307–314PubMedCrossRef

37.

Du XL, Fang S, Coker AL, Sanderson M, Aragaki C, Cormier JN, Xing Y, Gor BJ, Chan W (2006) Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma: findings from a large community-based cohort. Cancer 106(6):1276–1285. doi:10.1002/cncr.21732 PubMedCrossRef

38.

Saha S, Freeman M, Toure J, Tippens KM, Weeks C, Ibrahim S (2008) Racial and ethnic disparities in the VA health care system: a systematic review. J Gen Intern Med 23(5):654–671. doi:10.1007/s11606-008-0521-4 PubMedCentralPubMedCrossRef

39.

Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11:1388–1413PubMedCrossRef

Title: The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort
Authors: Alexis R. Gaines
Elizabeth L. Turner
Patricia G. Moorman
Stephen J. Freedland
Christopher J. Keto
Megan E. McPhail
Delores J. Grant
Adriana C. Vidal
Cathrine Hoyo
Publication date: 01-08-2014
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 8/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-014-0402-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2014

Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data

Body mass index and weight change in men with prostate cancer: progression and mortality

Assessment of a fully automated, high-throughput mammographic density measurement tool for use with processed digital mammograms

Serum uric acid levels and cancer mortality risk among males in a large general population-based cohort study

Different time trends by gender for the incidence of Hodgkin’s lymphoma among young adults in the USA: a birth cohort phenomenon

Age at first childbirth and oral contraceptive use are associated with risk of androgen receptor-negative breast cancer: the Malmö Diet and Cancer Cohort

Keynote webinar | Spotlight on antibody–drug conjugates in cancer